Clinical commentary on prophylactic treatment of radiation-induced xerostomiaCHAMBERS, Mark S.Archives of otolaryngology, head & neck surgery. 2003, Vol 129, Num 2, pp 251-252, issn 0886-4470, 2 p.Article

Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomiaWITSELL, David L; STINNETT, Sandra; CHAMBERS, Mark S et al.Head & neck. 2012, Vol 34, Num 8, pp 1136-1142, issn 1043-3074, 7 p.Article

A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparingROSENTHAL, David I; CHAMBERS, Mark S; WEBER, Randal S et al.Seminars in oncology. 2004, Vol 31, Num 6, pp 25-28, issn 0093-7754, 4 p., SUP18Conference Paper

An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABA_A α5 receptors with cognition enhancing propertiesCHAMBERS, Mark S; ATACK, John R; RYCROFT, W et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 24, pp 5829-5832, issn 0022-2623, 4 p.Article

Radiation-induced xerostomiaCHAMBERS, Mark S; ROSENTHAL, David I; WEBER, Randal S et al.Head & neck. 2007, Vol 29, Num 1, pp 58-63, issn 1043-3074, 6 p.Article

Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 1: FluoridesCHAMBERS, Mark S; MELLBERG, James R; KEENE, Harris J et al.Oral oncology (1997). 2006, Vol 42, Num 9, pp 934-945, issn 1368-8375, 12 p.Article

Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective TrialSCHWARTZ, David L; GARDEN, Adam S; THOMAS, Jimmy et al.International journal of radiation oncology, biology, physics. 2012, Vol 83, Num 3, pp 986-993, issn 0360-3016, 8 p.Article

Customization of the Voice Prosthesis to Prevent Leakage From the Enlarged Tracheoesophageal Puncture: Results of a Prospective TrialLEWIN, Jan S; HUTCHESON, Katherine A; BARRINGER, Denise A et al.The Laryngoscope. 2012, Vol 122, Num 8, pp 1767-1772, issn 0023-852X, 6 p.Article

THREE SYNCHRONOUS HPV-ASSOCIATED SQUAMOUS CELL CARCINOMAS OF WALDEYER'S RING: CASE REPORT AND COMPARISON WITH SLAUGHTER'S MODEL OF FIELD CANCERIZATIONMCGOVERN, Susan L; WILLIAMS, Michelle D; WEBER, Randal S et al.Head & neck. 2010, Vol 32, Num 8, pp 1118-1124, issn 1043-3074, 7 p.Article

Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patientsOH, Hee-Kyun; CHAMBERS, Mark S; GARDEN, Adam S et al.Journal of oral and maxillofacial surgery. 2004, Vol 62, Num 2, pp 139-144, issn 0278-2391, 6 p.Article

6,7-Dihydro-2-benzothiophen-4(5H)-ones: A novel class of GABA-A α5 receptor inverse agonistsCHAMBERS, Mark S; ATACK, John R; WAFFORD, Keith et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 6, pp 1176-1179, issn 0022-2623Article

Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancerRAO, Nikhil G; TROTTI, Andy; ROSENTHAL, David I et al.Oral oncology (1997). 2014, Vol 50, Num 8, pp 765-769, issn 1368-8375, 5 p.Article

ACUPUNCTURE FOR RADIATION-INDUCED XEROSTOMIA IN PATIENTS WITH CANCER: A PILOT STUDYGARCIA, M. Kay; CHIANG, Joseph S; CHAMBERS, Mark S et al.Head & neck. 2009, Vol 31, Num 10, pp 1360-1368, issn 1043-3074, 9 p.Article

Osteoradionecrosis of the Mandible: Treatment Outcomes and Factors Influencing the Progress of OsteoradionecrosisOH, Hee-Kyun; CHAMBERS, Mark S; MARTIN, Jack W et al.Journal of oral and maxillofacial surgery. 2009, Vol 67, Num 7, pp 1378-1386, issn 0278-2391, 9 p.Article

Pharmacokinetics and metabolism studies on 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA_A α5 inverse agonist for cognitive dysfunctionJONES, Philip; ATACK, John R; SZETO, Nicola et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 4, pp 872-875, issn 0960-894X, 4 p.Article

Radiation-induced xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and managementCHAMBERS, Mark S; GARDEN, Adam S; KIES, Merrill S et al.Head & neck. 2004, Vol 26, Num 9, pp 796-807, issn 1043-3074, 12 p.Article

A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and NeckLEWIS, Carol M; GLISSON, Bonnie S; WEBER, Randal S et al.Clinical cancer research (Print). 2012, Vol 18, Num 5, pp 1435-1446, issn 1078-0432, 12 p.Article

Measuring head and neck cancer symptom burden : The development and validation of the M. D. anderson symptom inventory, head and neck moduleROSENTHAL, David I; MENDOZA, Tito R; WANG, Xin S et al.Head & neck. 2007, Vol 29, Num 10, pp 923-931, issn 1043-3074, 9 p.Article

Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I studyCHAMBERS, Mark S; MELLBERG, James R; KEENE, Harris J et al.Oral oncology (1997). 2006, Vol 42, Num 9, pp 946-953, issn 1368-8375, 8 p.Article

Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: A pilot studyCHAMBERS, Mark S; KEENE, Harris J; TOTH, Béla B et al.Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2005, Vol 99, Num 2, pp 180-184, issn 1079-2104, 5 p.Article

3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of α5-containing GABA_A receptorsSZEKERES, Helen J; ATACK, John R; CHAMBERS, Mark S et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 11, pp 2871-2875, issn 0960-894X, 5 p.Article

Identification of a novel, selective GABA_A a5 receptor inverse agonist which enhances cognitionCHAMBERS, Mark S; ATACK, John R; REEVE, Austin J et al.Journal of medicinal chemistry (Print). 2003, Vol 46, Num 11, pp 2227-2240, issn 0022-2623, 14 p.Article